Table 2.

Treatment Characteristics and Clinical Response to Therapy

Dose (mg/kg)	No. of Patients	Total No. of Doses					Best Response (duration in months)*
		1	2	3	5	11
0.3	6	6	0	0	0	0	N/A
1	6	3	1	1	1	0	1 MXR (1)
3	6	3	0	2	1	0	1 CR (21+)†
10	21	15	1	4	0	1	2 PR (3+, 16+)‡§
							1 MXR (1)
Total	39	27	2	7	2	1	1 CR, 2 PR, 2 MXR

Abbreviations: N/A, not applicable; MXR, mixed response defined as regression in some lesions but concomitant progression in others; CR, complete response; PR, partial response.

^*CR and PR by Response Evaluation Criteria in Solid Tumors 1.0 criteria.

^†This patient with stage IV colorectal cancer had previously shown progressive disease after receiving chemotherapy regimens including bevacizumab and cetuximab.

^‡PR duration of 3+ months was preceded by an MXR in this patient with melanoma lasting 20 months. Previous therapies that were ineffective included high-dose interleukin-2 and temozolomide.

^§PR duration of 16+ months was preceded by an MXR in this patient with renal cell carcinoma lasting 4 months. Previous therapies that were ineffective included sunitinib, sorafenib, and an experimental histone deacetylase inhibitor.